The Endocannabinoid System and Cannabidiol's Promise for the Treatment of Substance Use Disorder
Open accessThe DOI matches its Crossref record; 37 of the 37 references it cites were found in a registry or an index.
Abstract
Substance use disorder is characterized by repeated use of a substance, leading to clinically significant distress, making it a serious public health concern. The endocannabinoid system plays an important role in common neurobiological processes underlying substance use disorder, in particular by mediating the rewarding and motivational effects of substances and substance-related cues. In turn, a number of cannabinoid drugs (e.g., rimonabant, nabiximols) have been suggested for potential pharmacological treatment for substance dependence. Recently, cannabidiol (CBD), a non-psychoactive phytocannabinoid found in the cannabis plant, has also been proposed as a potentially effective treatment for the management of substance use disorder. Animal and human studies suggest that these cannabinoids have the potential to reduce craving and relapse in abstinent substance users, by impairing reconsolidation of drug-reward memory, salience of drug cues, and inhibiting the reward-facilitating effect of drugs. Such functions likely arise through the targeting of the endocannabinoid and serotonergic systems, although the exact mechanism is yet to be elucidated. This article seeks to review the role of the endocannabinoid system in substance use disorder and the proposed pharmacological action supporting cannabinoid drugs' therapeutic potential in addictions, with a focus on CBD. Subsequently, this article will evaluate the underlying evidence for CBD as a potential treatment for substance use disorder, across a range of substances including nicotine, alcohol, psychostimulants, opioids, and cannabis. While early research supports CBD's promise, further investigation and validation of CBD's efficacy, across preclinical and clinical trials will be necessary.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Di Chiara, G., & Imperato, A. (1988) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.85.14.5274 · Cited by 4,733
What is the role of dopamine in reward: hedonic impact, reward learning, or incentive salience?
Berridge, K. C., & Robinson, T. E. (1998) · Brain Research Reviews · doi:10.1016/s0165-0173(98)00019-8 · Cited by 4,127
Dysfunction of the prefrontal cortex in addiction: neuroimaging findings and clinical implications
Goldstein, R. Z., & Volkow, N. D. (2011) · Nature Reviews Neuroscience · doi:10.1038/nrn3119 · Cited by 2,749
Drug Dependence, a Chronic Medical Illness
McLellan, A. T., Lewis, D. C., O'Brien, C. P., & Kleber, H. D. (2000) · JAMA · doi:10.1001/jama.284.13.1689 · Cited by 2,622 · cited 1×
“Treatment to date has had minimal success, with a high likelihood of relapse (3).”
BackgroundCannabinoid receptor localization in brain.
Herkenham, M., Lynn, A. B., Little, M. D., Johnson, M. R., Melvin, L. S., de Costa, B. R., & Rice, K. C. (1990) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.87.5.1932 · Cited by 2,321 · cited 1×
“CB1Rs are one of the most common G-proteincoupled receptors in the central nervous system, preferentially residing on presynaptic neurons across diverse regions including the neocortex, striatum, and hippocampus (10, 11).”
BackgroundCellular and molecular mechanisms of drug dependence
Koob, G. F., & Bloom, F. E. (1988) · Science · doi:10.1126/science.2903550 · Cited by 2,070
The psychology and neurobiology of addiction: an incentive–sensitization view
Robinson, T. E., & Berridge, K. C. (2000) · Addiction · doi:10.1046/j.1360-0443.95.8s2.19.x · Cited by 1,507 · cited 1×
“Several lines of thought suggest SUD to be a learned habit (48, 49) mediated by persistent changes in striatal function (e.”
BackgroundAddiction, a disease of compulsion and drive: involvement of the orbitofrontal cortex
Volkow, N. D. (2000) · Cerebral Cortex · doi:10.1093/cercor/10.3.318 · Cited by 1,240
Efficacy and safety of the weight-loss drug rimonabant: a meta-analysis of randomised trials
Christensen, R., Kristensen, P. K., Bartels, E. M., Bliddal, H., & Astrup, A. (2007) · The Lancet · doi:10.1016/s0140-6736(07)61721-8 · Cited by 1,097 · cited 1×
“Despite promising findings of rimonabant against substance use and relapse, it has been found to produce significant negative psychiatric effects including depression, anxiety, and an elevated suicide rate, preventing it from being a viable treatment option (98).”
BackgroundThe endocannabinoid system and its therapeutic exploitation
Marzo, V. D., Bifulco, M., & Petrocellis, L. D. (2004) · Nature Reviews Drug Discovery · doi:10.1038/nrd1495 · Cited by 1,090
Effects of nicotine on the nucleus accumbens and similarity to those of addictive drugs.
Pontieri, F. E., Tanda, G., Orzi, F., & Chiara, G. D. (1996) · Nature · doi:10.1038/382255a0 · Cited by 1,073 · cited 1×
“are suggested to be related to increased DA in striatal and limbic (NAc and amygdala) regions (44, 45); the latter reflects further compulsive substance intake, loss of control, and persistent intake despite the substance’s adverse effects and tolerance to its pleasurable responses (44, 46, 47).”
BackgroundGlass, M., Faull, R. L. M., & Dragunow, M. (1997) · Neuroscience · doi:10.1016/s0306-4522(96)00428-9 · Cited by 1,052 · cited 9×
“Only psychostimulants are suggested to act directly on DAergic axon terminals in the NAc, potentially avoiding upstream endocannabinoid involvement in the VTA (35).”
BackgroundInfluentialCannabidiol is a negative allosteric modulator of the cannabinoid CB 1 receptor
Laprairie, R. B., Bagher, A. M., Kelly, M. E. M., & Denovan‐Wright, E. M. (2015) · British Journal of Pharmacology · doi:10.1111/bph.13250 · Cited by 1,039 · cited 2×
“Within the cannabinoid system, it is a non-competitive antagonist of CB1R with a low affinity for CB1Rs’ primary ligand site (104, 105), instead acting through negative allosteric modulation (105, 106).”
Dopamine responses comply with basic assumptions of formal learning theory
Waelti, P., Dickinson, A., & Schultz, W. (2001) · Nature · doi:10.1038/35083500 · Cited by 1,018
De Petrocellis, L., Ligresti, A., Moriello, A. S., Allarà, M., Bisogno, T., Petrosino, S., Stott, C. G., & Di Marzo, V. (2011) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2010.01166.x · Cited by 946
The addicted human brain: insights from imaging studies
Volkow, N. D., Fowler, J. S., & Wang, G.-J. (2003) · Journal of Clinical Investigation · doi:10.1172/jci18533 · Cited by 916
Agonistic properties of cannabidiol at 5-HT1a receptors
Russo, E. B., Burnett, A., Hall, B., & Parker, K. K. (2005) · Neurochemical Research · doi:10.1007/s11064-005-6978-1 · Cited by 878 · cited 2×
“CBD is non-rewarding, and acts on a number of receptor systems including the opioid (101), serotonergic (102, 103), and cannabinoid (22) systems.”
BackgroundIffland, K., & Grotenhermen, F. (2017) · Cannabis & Cannabinoid Research · doi:10.1089/can.2016.0034 · Cited by 645
Safety and side effects of cannabidiol, a Cannabis sativa constituent
Machado Bergamaschi, M., Helena Costa Queiroz, R., Waldo Zuardi, A., & Alexandre S. Crippa, J. (2011) · Current Drug Safety · doi:10.2174/157488611798280924 · Cited by 558
It could be habit forming: drugs of abuse and striatal synaptic plasticity
Gerdeman, G. L., Partridge, J. G., Lupica, C. R., & Lovinger, D. M. (2003) · Trends in Neurosciences · doi:10.1016/s0166-2236(03)00065-1 · Cited by 480
Fusar-Poli, P., Crippa, J. A., Bhattacharyya, S., Borgwardt, S. J., Allen, P., Martin-Santos, R., Seal, M., Surguladze, S. A., O’Carrol, C., Atakan, Z., et al. (2009) · Archives of General Psychiatry · doi:10.1001/archgenpsychiatry.2008.519 · Cited by 465
Cohen, C., Perrault, G., Voltz, C., Steinberg, R., & Soubrié, P. (2002) · Behavioural Pharmacology · doi:10.1097/00008877-200209000-00018 · Cited by 396 · cited 1×
“Antagonism of CB1R by rimonabant, reduces alcohol-induced sensitization and reinstatement of nicotine-seeking in rats (83, 84, 86).”
BackgroundEndocannabinoid signaling system and brain reward: emphasis on dopamine
GARDNER, E. (2005) · Pharmacology Biochemistry and Behavior · doi:10.1016/j.pbb.2005.01.032 · Cited by 387
Imaging endogenous dopamine competition with [11C]raclopride in the human brain
Volkow, N. D., Wang, G., Fowler, J. S., Logan, J., Schlyer, D., Hitzemann, R., Lieberman, J., Angrist, B., Pappas, N., MacGregor, R., et al. (1994) · Synapse · doi:10.1002/syn.890160402 · Cited by 379 · cited 1×
“The acute reinforcing effect of addictive substances is thought to be due to their direct or indirect activation of DA neurons along this pathway (16).”
BackgroundCampos, A. C., & Guimarães, F. S. (2008) · Psychopharmacology · doi:10.1007/s00213-008-1168-x · Cited by 364
Rios, C., Gomes, I., & Devi, L. A. (2006) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0706757 · Cited by 327
Translational investigation of the therapeutic potential of Cannabidiol (CBD): Toward a new age
Crippa, J. A., Guimarães, F. S., Campos, A. C., & Zuardi, A. W. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.02009 · Cited by 308 · cited 7×
“CBD’s capacity to alleviate stress, anxiety, and depressive symptoms may be mediating its treatment effect on SUDs (124, 153, 154).”
BackgroundInfluentialMarijuana and cannabinoid regulation of brain reward circuits
Lupica, C. R., Riegel, A. C., & Hoffman, A. F. (2004) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0705931 · Cited by 289 · cited 10×
“Only psychostimulants are suggested to act directly on DAergic axon terminals in the NAc, potentially avoiding upstream endocannabinoid involvement in the VTA (35).”
BackgroundInfluentialNabiximols as an Agonist Replacement Therapy During Cannabis Withdrawal: A Randomized Clinical Trial
Allsop, D. J., Copeland, J., Lintzeris, N., Dunlop, A. J., Montebello, M., Sadler, C., Rivas, G. R., Holland, R. M., Muhleisen, P., Norberg, M. M., et al. (2014) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2013.3947 · Cited by 266
Cohen, C., Perrault, G., Griebel, G., & Soubrié, P. (2005) · Neuropsychopharmacology · doi:10.1038/sj.npp.1300541 · Cited by 251
Levin, F. R., Mariani, J. J., Brooks, D. J., Pavlicova, M., Cheng, W., & Nunes, E. V. (2011) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2010.12.010 · Cited by 232
Ren, Y., Whittard, J., Higuera-Matas, A., Morris, C. V., & Hurd, Y. L. (2009) · The Journal of Neuroscience · doi:10.1523/jneurosci.4291-09.2009 · Cited by 210 · cited 5×
“(115) Rats Heroin CBD (5–20 mg/kg) Self-administration”
BackgroundInfluentialParker, L. A., Burton, P., Sorge, R. E., Yakiwchuk, C., & Mechoulam, R. (2004) · Psychopharmacology · doi:10.1007/s00213-004-1825-7 · Cited by 171
Fusar-Poli, P., Allen, P., Bhattacharyya, S., Crippa, J. A., Mechelli, A., Borgwardt, S., Martin-Santos, R., Seal, M. L., O'Carrol, C., Atakan, Z., et al. (2010) · The International Journal of Neuropsychopharmacology · doi:10.1017/s1461145709990617 · Cited by 163 · cited 1×
“Recent evidence suggests that within the mesolimbic system, CBD also influences the serotonergic system, as an agonist of the serotonin 1A (5HT1A) receptor (102, 103), which in addition to contributing to reduction in stress and anxiety (150), may be responsible for (i) blunting the reward-facilitating effect of subst…”
BackgroundCrippa, J. A. S., Hallak, J. E. C., Machado-de-Sousa, J. P., Queiroz, R. H. C., Bergamaschi, M., Chagas, M. H. N., & Zuardi, A. W. (2013) · Journal of Clinical Pharmacy and Therapeutics · doi:10.1111/jcpt.12018 · Cited by 101 · cited 1×
“In human case studies, CBD has also been found to reduce selfreported cannabis use to non-use in a dependent male (128), and to reduced cannabis withdrawal in another (135), although the latter case study did find the subject to have relapsed after a 6months follow up (135).”
BackgroundEffects of fixed or self-titrated dosages of Sativex on cannabis withdrawal and cravings.
Trigo, J. M., Lagzdins, D., Rehm, J., Selby, P., Gamaleddin, I., Fischer, B., Barnes, A. J., Huestis, M. A., & Le Foll, B. (2016) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2016.02.020 · Cited by 97 · cited 1×
“Further casecontrol studies indicate nabiximols to be effective in reducing withdrawal, but not cannabis use (123, 130, 144).”
BackgroundZuardi, A. W., Hallak, J. E. C., & Crippa, J. A. S. (2012) · Psychopharmacology · doi:10.1007/s00213-011-2495-x · Cited by 84 · cited 1×
“, whether CBD is administered in conjunction with, prior to, or post substance-use), and dose ratio (117).”
Cited by
Cannabis sativa: Much more beyond Δ9-tetrahydrocannabinol
Alves, P., Amaral, C., Teixeira, N., & Correia-da-Silva, G. (2020) · Pharmacological Research · doi:10.1016/j.phrs.2020.104822 · Cited by 135
Spanagel, R. (2020) · Dialogues in Clinical Neuroscience · doi:10.31887/dcns.2020.22.3/rspanagel · Cited by 127
Distinct functions of endogenous cannabinoid system in alcohol abuse disorders
Basavarajappa, B. S., Joshi, V., Shivakumar, M., & Subbanna, S. (2019) · British Journal of Pharmacology · doi:10.1111/bph.14780 · Cited by 37
Bhardwaj, A. K., Mills, L., Doyle, M., Sahid, A., Montebello, M., Monds, L., Arunogiri, S., Haber, P., Lorenzetti, V., Lubman, D. I., et al. (2024) · BMC Psychiatry · doi:10.1186/s12888-024-05616-3 · Cited by 10
“…studies examining other addictive drugs, CBD has been found to significantly reduce cue-induced craving and anxiety during abstinence from heroin [34] and cigarette use among tobacco smokers [35], but was not effective in reducing relapse or cravings in a placebo-controlled randomised trial for…”
Background
Metadata
- Authors
- Chye, Y., Christensen, E., Solowij, N., & Yücel, M.
- Venue
- Frontiers in Psychiatry
- Publisher
- Frontiers Media SA
- Published
- 2019-02-19
- Volume
- 10
- Pages
- 63-63
- ISSN
- 1664-0640 (ISSN-L)
- OpenAlex
- W2915849435
- Cited by
- 126
- References
- 37
- FWCI
- 11.36
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.